Targeting Ezh2 Could Overcome Docetaxel Resistance in Prostate Cancer Cells

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Jan 10

PMID 30621625

Citations 13

Authors

Xiaofu Qiu

Wei Wang

Bijun Li

Bo Cheng

Kangjian Lin

Jian Bai

Huanhui Li

Guosheng Yang

Affiliations

Soon will be listed here.

Abstract

Background: Docetaxel was used to treat metastatic CRPC patients. However, Doc resistance in prostate cancer (PCa) hinders its clinical application.

Objective: To understand the underlying mechanisms by which Doc resistance is developed and to find novel therapeutic target to cure Doc resistant PCa has clinical importance.

Methods: We established Doc resistant cell lines and explored the role of Ezh2 in the development of Doc resistance by overexpressing its cDNA or using its inhibitor.

Results: We found that Ezh2 was induced in our established Doc resistant (DocR) cells, which was attributable to the silenced expression of miR-101-3p and miR-138-5p. Blockage of Ezh2 activity by either inhibitor or miRNA mimics could overcome Doc resistance by suppressing Doc-induced cancer stem cells populations. Mechanistically, Ezh2 activity was required for the induced expression of Nanog, Sox2 and CD44 upon Doc treatment.

Conclusions: Targeting Ezh2 could overcome Doc resistance.

Citing Articles

Treating human cancer by targeting EZH2.

Xu M, Xu C, Wang R, Tang Q, Zhou Q, Wu W Genes Dis. 2025; 12(3):101313.

PMID: 40028035 PMC: 11870178. DOI: 10.1016/j.gendis.2024.101313.

Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2.

Lee W, Kim S, Kim S, Yoon J, Moon K, Cheon S World J Mens Health. 2023; 41(3):649-658.

PMID: 36593705 PMC: 10307646. DOI: 10.5534/wjmh.220073.

Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment.

Elrakaybi A, Ruess D, Lubbert M, Quante M, Becker H Cancers (Basel). 2022; 14(23).

PMID: 36497404 PMC: 9738647. DOI: 10.3390/cancers14235926.

EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies.

Samarzija I, Tomljanovic M, Novak Kujundzic R, Gall Troselj K Cancers (Basel). 2022; 14(19).

PMID: 36230683 PMC: 9561994. DOI: 10.3390/cancers14194761.

miRNome Profiling Reveals Shared Features in Breast Cancer Subtypes and Highlights miRNAs That Potentially Regulate MYB and EZH2 Expression.

Correa S, Lopes F, Panis C, Basili T, Binato R, Abdelhay E Front Oncol. 2021; 11:710919.

PMID: 34646766 PMC: 8502886. DOI: 10.3389/fonc.2021.710919.

References

Heinlein C, Chang C . Androgen receptor in prostate cancer. Endocr Rev. 2004; 25(2):276-308. DOI: 10.1210/er.2002-0032. View

Morse D, Gray H, Payne C, Gillies R . Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 2005; 4(10):1495-504. DOI: 10.1158/1535-7163.MCT-05-0130. View

Valencia-Sanchez M, Liu J, Hannon G, Parker R . Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006; 20(5):515-24. DOI: 10.1101/gad.1399806. View

Ramaswamy B, Puhalla S . Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc). 2006; 42(4):265-79. DOI: 10.1358/dot.2006.42.4.968648. View

Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K . Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006; 12(20 Pt 1):6116-24. DOI: 10.1158/1078-0432.CCR-06-0147. View

Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R . Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008; 101(3):308-12. DOI: 10.1111/j.1464-410X.2007.07331.x. View

Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, Ulivi P . Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol. 2008; 217(2):494-501. DOI: 10.1002/jcp.21522. View

Reuter C, Morgan M, Ivanyi P, Fenner M, Ganser A, Grunwald V . Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J Urol. 2010; 28(3):391-8. DOI: 10.1007/s00345-010-0527-5. View

Cao P, Deng Z, Wan M, Huang W, Cramer S, Xu J . MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010; 9:108. PMC: 2881117. DOI: 10.1186/1476-4598-9-108. View

10.

Zhu M, Horbinski C, Garzotto M, Qian D, Beer T, Kyprianou N . Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70(20):7992-8002. PMC: 2978028. DOI: 10.1158/0008-5472.CAN-10-0585. View

11.

Margueron R, Reinberg D . The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469(7330):343-9. PMC: 3760771. DOI: 10.1038/nature09784. View

12.

Colloca G, Venturino A, Checcaglini F . Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review. Med Oncol. 2011; 29(2):776-85. DOI: 10.1007/s12032-011-9855-6. View

13.

ONeill A, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher W . Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011; 10:126. PMC: 3203088. DOI: 10.1186/1476-4598-10-126. View

14.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L . Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One. 2012; 7(3):e33729. PMC: 3307758. DOI: 10.1371/journal.pone.0033729. View

15.

Hwang C . Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol. 2012; 4(6):329-40. PMC: 3481557. DOI: 10.1177/1758834012449685. View

16.

Asangani I, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju L . Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2012; 49(1):80-93. PMC: 3547524. DOI: 10.1016/j.molcel.2012.10.008. View

17.

Xu K, Wu Z, Groner A, He H, Cai C, Lis R . EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012; 338(6113):1465-9. PMC: 3625962. DOI: 10.1126/science.1227604. View

18.

van Vlerken L, Kiefer C, Morehouse C, Li Y, Groves C, Wilson S . EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med. 2013; 2(1):43-52. PMC: 3659740. DOI: 10.5966/sctm.2012-0036. View

19.

Yang Y, Yu J . EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013; 4(5):331-41. PMC: 4131440. DOI: 10.1007/s13238-013-2093-2. View

20.

Li K, Liu C, Zhou B, Bi L, Huang H, Lin T . Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci. 2013; 14(6):11981-93. PMC: 3709767. DOI: 10.3390/ijms140611981. View